Sifting through countless of stocks in the Health Care Equipment & Supplies industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in TransMedics Group, Inc., Pacific Biosciences of California or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how TransMedics Group, Inc., Pacific Biosciences of California and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About TransMedics Group, Inc., Pacific Biosciences of California and Inc.

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, the company provides Revio, Vega, and Sequel instruments which conduct, monitor, and analyze single-molecule biochemical reactions on SMRT cell microchips; short-read sequencing; and onso instrument. It serves academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations, pharmaceutical companies, and agricultural companies. The company markets its products through a sales force and distribution partners in Australia, certain parts of Asia, Europe, the Middle East, Africa, Central America, and South America. It has a collaboration with DNAstack Inc. to provide federated dataset of HiFi whole genome sequencing data. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

Latest Health Care Equipment & Supplies and TransMedics Group, Inc., Pacific Biosciences of California, Inc. Stock News

As of October 9, 2026, TransMedics Group, Inc. had a $2.7 billion market capitalization, compared to the Health Care Equipment & Supplies median of $385.5 million. TransMedics Group, Inc.’s stock is down 36% in 2026, down 2.4% in the previous five trading days and down 34.04% in the past year.

Currently, TransMedics Group, Inc.’s price-earnings ratio is 19.4. TransMedics Group, Inc.’s trailing 12-month revenue is $668.5 million with a 22.7% net profit margin. Year-over-year quarterly sales growth most recently was 20.6%. Analysts expect adjusted earnings to reach $1.513 per share for the current fiscal year. TransMedics Group, Inc. does not currently pay a dividend.

As of October 9, 2026, Pacific Biosciences of California, Inc. had a $724.2 million market cap, putting it in the 42nd percentile of all stocks. Pacific Biosciences of California, Inc.’s stock is up 24.6% in 2026, down 8.3% in the previous five trading days and up 54.31% in the past year.

Currently, Pacific Biosciences of California, Inc. does not have a price-earnings ratio. Pacific Biosciences of California, Inc.’s trailing 12-month revenue is $159.3 million with a -82.5% net profit margin. Year-over-year quarterly sales growth most recently was -2.0%. Analysts expect adjusted earnings to reach $-0.518 per share for the current fiscal year. Pacific Biosciences of California, Inc. does not currently pay a dividend.

How We Compare TransMedics Group, Inc., Pacific Biosciences of California and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at TransMedics Group, Inc., Pacific Biosciences of California and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

TransMedics Group, Inc., Pacific Biosciences of California and Inc. Stock Value Grades

Company	Ticker	Value
TransMedics Group, Inc.	TMDX	F
Pacific Biosciences of California, Inc.	PACB	na

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

TransMedics Group, Inc. has a Value Score of 16, which is Ultra Expensive. Pacific Biosciences of California, Inc. does not have a meaningful Value Score.

The Value Stock Winner: No Clear Winner

Neither TransMedics Group, Inc., Pacific Biosciences of California or Inc. has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if TransMedics Group, Inc., Pacific Biosciences of California or Inc. is the better investment when it comes to value.

TransMedics Group, Inc., Pacific Biosciences of California and Inc.’s Quality Grades

Company	Ticker	Quality
TransMedics Group, Inc.	TMDX	D
Pacific Biosciences of California, Inc.	PACB	F

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

TransMedics Group, Inc. has a Quality Score of 37, which is Weak. Pacific Biosciences of California, Inc. has a Quality Score of 14, which is Very Weak.

The Quality Stock Winner: No Clear Winner

Neither TransMedics Group, Inc., Pacific Biosciences of California or Inc. has a high enough Quality Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if TransMedics Group, Inc., Pacific Biosciences of California or Inc. is the better investment when it comes to quality.

TransMedics Group, Inc., Pacific Biosciences of California and Inc.’s Momentum Grades

Company	Ticker	Momentum
TransMedics Group, Inc.	TMDX	D
Pacific Biosciences of California, Inc.	PACB	A

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

TransMedics Group, Inc. has a Momentum Score of 35, which is Weak. Pacific Biosciences of California, Inc. has a Momentum Score of 93, which is Very Strong.

The Momentum Grade Winner: Pacific Biosciences of California, Inc.

As you can clearly see from the Momentum Grade breakdown above, Pacific Biosciences of California, Inc. is considered to have stronger momentum compared to TransMedics Group, Inc.. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Pacific Biosciences of California, Inc. could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other TransMedics Group, Inc., Pacific Biosciences of California and Inc. Grades

In addition to Value, Quality and Momentum, A+ Investor also provides grades for Growth and Estimate Revisions.

Earnings estimate revisions scores take into account the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, surprises beget further surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether TransMedics Group, Inc., Pacific Biosciences of California and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, TransMedics Group, Inc., Pacific Biosciences of California or Inc. Stock?

Overall, TransMedics Group, Inc. stock has a Value Score of 16, Momentum Score of 35 and Quality Score of 37.

Pacific Biosciences of California, Inc. stock has a Value Score of , Momentum Score of 93 and Quality Score of 14.

Comparing TransMedics Group, Inc., Pacific Biosciences of California and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.